4//SEC Filing
Valantine Hannah 4
Accession 0000950170-25-091762
CIK 0001743881other
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 5:51 PM ET
Size
9.6 KB
Accession
0000950170-25-091762
Insider Transaction Report
Form 4
Valantine Hannah
Director
Transactions
- Sale
Common Stock
2025-06-26$44.01/sh−1,542$67,863→ 7,465 total - Sale
Common Stock
2025-06-26$44.11/sh−876$38,640→ 9,007 total - Sale
Common Stock
2025-06-26$44.13/sh−398$17,562→ 2,289 total(indirect: By Spouse) - Sale
Common Stock
2025-06-26$44.03/sh−1,891$83,261→ 398 total(indirect: By Spouse)
Footnotes (2)
- [F1]Represents the weighted average sale price of the shares sold from $44.025 to $44.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F2]Represents the weighted average sale price of the shares sold from $44.12 to $44.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001855608
Filing Metadata
- Form type
- 4
- Filed
- Jun 29, 8:00 PM ET
- Accepted
- Jun 30, 5:51 PM ET
- Size
- 9.6 KB